Hard to heal pressure ulcers (stage III–IV): Efficacy of injected activated macrophage suspension (AMS) as compared with standard of care (SOC) treatment controlled trial

Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis

“…Moreover, although most of the performed studies do not report any adverse effects of MSC treatment, concerns about safety related to tumour progression/promotion still need to be resolved 31–34. Monocytes/macrophages are non-oncogenic and human MΦreg can readily be generated from peripheral blood monocytes and be administered safely through central venous infusion,35 and have been used for promoting transplant tolerance36 and for the treatment of chronic wounds 37…”

Drug delivery strategies to control macrophages for tissue repair and regeneration

“…In their phase 3-4 clinical trial, 85.1% of the macrophage-treated group (120 out of 141 ulcers) achieved at least 50% closure in a time frame ranging from 14 to 171 days. 44 On the other hand, in the control group that was treated with the standard of care, only 41.3% (31 out of 75 ulcers) achieved 50% area closure in 26 to 368 days. 44 Leor et al 45 studied the impact of directly injecting macrophages to ischemic myocardial tissue in a rat model.…”

“…44 On the other hand, in the control group that was treated with the standard of care, only 41.3% (31 out of 75 ulcers) achieved 50% area closure in 26 to 368 days. 44 Leor et al 45 studied the impact of directly injecting macrophages to ischemic myocardial tissue in a rat model. Human macrophages were isolated from peripheral blood, activated in vitro by a novel method based on hypoosmotic shock, and directly injected into the ischemic cardiac tissue 1 min after the induction of myocardial infarction.…”

“…For example, Zuloff-Shani et al 44 evaluated the efficacy of allogeneic macrophage suspensions for treating chronic pressure ulcers. In their phase 3-4 clinical trial, 85.1% of the macrophage-treated group (120 out of 141 ulcers) achieved at least 50% closure in a time frame ranging from 14 to 171 days.…”

The Role of Myeloid Lineage Cells on Skin Healing and Skin Regeneration

“…Researchers found that repeated injections of macrophages after chronic sulfur mustard wounds found significantly decreased wound area and improved barrier function at 10 days post-injury [126]. In a two-arm, non-parallel, open controlled trial tested the efficacy of macrophage injection in treating stage III and stage IV pressure ulcers in 100 elderly patients [127], injection of human activated macrophages in suspension was safe and showed efficacy by improving wound closure rates [127]. Topical application of the macrophage activator, glucan, improves wound healing by increasing macrophage numbers and improving re-epithelialization [128,129].…”